CVRx (CVRX)
(Delayed Data from NSDQ)
$13.40 USD
+0.28 (2.13%)
Updated Nov 1, 2024 04:00 PM ET
After-Market: $16.02 +2.62 (19.55%) 7:58 PM ET
3-Hold of 5 3
F Value D Growth D Momentum F VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$13.40 USD
+0.28 (2.13%)
Updated Nov 1, 2024 04:00 PM ET
After-Market: $16.02 +2.62 (19.55%) 7:58 PM ET
3-Hold of 5 3
F Value D Growth D Momentum F VGM
Zacks News
CVRx (CVRX) Reports Q3 Loss, Tops Revenue Estimates
by Zacks Equity Research
CVRx (CVRX) delivered earnings and revenue surprises of -26.67% and 0.70%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?
CVRx (CVRX) Soars 17.2%: Is Further Upside Left in the Stock?
by Zacks Equity Research
CVRx (CVRX) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
Masimo (MASI) Surges 8.7%: Is This an Indication of Further Gains?
by Zacks Equity Research
Masimo (MASI) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
CVRX Stock Gains on Unveiling of Barostim's Positive Study Data
by Zacks Equity Research
CVRx announces the publication of positive study data for its Barostim therapy.
CVRx (CVRX) Reports Q2 Loss, Lags Revenue Estimates
by Zacks Equity Research
CVRx (CVRX) delivered earnings and revenue surprises of -27.45% and 0.28%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?
Intuitive Surgical, Inc. (ISRG) Tops Q2 Earnings and Revenue Estimates
by Zacks Equity Research
Intuitive Surgical (ISRG) delivered earnings and revenue surprises of 16.34% and 2.02%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?
Strength Seen in CVRx (CVRX): Can Its 19.0% Jump Turn into More Strength?
by Zacks Equity Research
CVRx (CVRX) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
Strength Seen in Silk Road Medical (SILK): Can Its 24.0% Jump Turn into More Strength?
by Zacks Equity Research
Silk Road Medical (SILK) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
CVRx (CVRX) Stock Jumps 33.9%: Will It Continue to Soar?
by Zacks Equity Research
CVRx (CVRX) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
CVRx's (CVRX) Latest Data Favors Barostim's Long-Term Benefits
by Zacks Equity Research
CVRx's (CVRX) announcement of the availability of additional data supporting the long-term benefits of Barostim is likely to lead to improved patient care.
New Strong Buy Stocks for January 30th
by Zacks Equity Research
HCC, EGO, WRLD, PBPB and CVRX have been added to the Zacks Rank #1 (Strong Buy) List on January 30, 2024.
CVRx (CVRX) Reports Q4 Loss, Tops Revenue Estimates
by Zacks Equity Research
CVRx (CVRX) delivered earnings and revenue surprises of 20% and 3.72%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?
CVRx (CVRX) Upgraded to Strong Buy: What Does It Mean for the Stock?
by Zacks Equity Research
CVRx (CVRX) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
What Makes CVRx (CVRX) a Good Fit for 'Trend Investing'
by Zacks Equity Research
CVRx (CVRX) could be a great choice for investors looking to make a profit from fundamentally strong stocks that are currently on the move. It is one of the several stocks that made it through our "Recent Price Strength" screen.
Take the Zacks Approach to Beat the Market: Boeing, McDonald's, Monster Beverage in Focus
by Abhinab Dasgupta
Last week, our time-tested methodologies served investors well in navigating the market. Check out some of our achievements from the past three months.
AngioDynamics (ANGO) Reports Q2 Loss, Misses Revenue Estimates
by Zacks Equity Research
AngioDynamics (ANGO) delivered earnings and revenue surprises of 44.44% and 3.15%, respectively, for the quarter ended November 2023. Do the numbers hold clues to what lies ahead for the stock?
CVRx (CVRX) Moves 24.2% Higher: Will This Strength Last?
by Zacks Equity Research
CVRx (CVRX) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
Here's Why 'Trend' Investors Would Love Betting on CVRx (CVRX)
by Zacks Equity Research
CVRx (CVRX) could be a great choice for investors looking to make a profit from fundamentally strong stocks that are currently on the move. It is one of the several stocks that made it through our "Recent Price Strength" screen.
CVRx (CVRX) Is Up 10.17% in One Week: What You Should Know
by Zacks Equity Research
Does CVRx (CVRX) have what it takes to be a top stock pick for momentum investors? Let's find out.
CVRx (CVRX) is on the Move, Here's Why the Trend Could be Sustainable
by Zacks Equity Research
CVRx (CVRX) made it through our "Recent Price Strength" screen and could be a great choice for investors looking to make a profit from stocks that are currently on the move.
CVRx (CVRX) Moves 7.1% Higher: Will This Strength Last?
by Zacks Equity Research
CVRx (CVRX) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
Is Corbus Pharmaceuticals (CRBP) Stock Outpacing Its Medical Peers This Year?
by Zacks Equity Research
Here is how Corbus Pharmaceuticals (CRBP) and CVRx (CVRX) have performed compared to their sector so far this year.
Recent Price Trend in CVRx (CVRX) is Your Friend, Here's Why
by Zacks Equity Research
CVRx (CVRX) made it through our "Recent Price Strength" screen and could be a great choice for investors looking to make a profit from stocks that are currently on the move.
CVRx (CVRX) is on the Move, Here's Why the Trend Could be Sustainable
by Zacks Equity Research
CVRx (CVRX) made it through our "Recent Price Strength" screen and could be a great choice for investors looking to make a profit from stocks that are currently on the move.
What Makes CVRx (CVRX) a New Strong Buy Stock
by Zacks Equity Research
CVRx (CVRX) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.